Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q3 FY26
Arrowhead Pharmaceuticals (ARWR) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 4, 2026
Arrowhead Pharmaceuticals (ARWR) reported revenue of $75.3M for the third quarter fiscal 2026 (Q3 FY26), +171% from a year earlier and +2% from the quarter before. Operating margin was -226.0%, net loss $179M (237.8% of revenue).
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $75.3M | +2% | +171% |
| Operating profit | −$170M | — | — |
| Net earnings | −$179M | — | — |
| Operating cash flow | −$177M | -310% | — |
What changed
Revenue was $75.3M in Q3 FY26, up 171% year over year and up 2% from the previous quarter.
Operating costs exceeded revenue by $170.1M, an operating margin of -226.0%. Total costs grew 27% against revenue growth of 171%. The fastest-growing cost line was SG&A (+52%). The quarter ended with a net loss of $178.9M, wider than the previous quarter's $137.6M loss.
Operating cash flow was −$177.5M. Non-cash charges added back $6.2M of depreciation and amortization and $14.9M of share-based compensation. Working capital and other items used $19.6M. Capital expenditures of $3.9M exceeded it, leaving free cash flow of −$181.3M.
Questions
What was Arrowhead Pharmaceuticals' revenue in the third quarter fiscal 2026?
Arrowhead Pharmaceuticals (ARWR) reported revenue of $75.3M for the third quarter fiscal 2026 (Q3 FY26), +171% from a year earlier and +2% from the quarter before.
Was Arrowhead Pharmaceuticals profitable in the third quarter fiscal 2026?
Operating loss was $170M (-226.0% of revenue) and net loss $179M.